文献速递消化道肿瘤放疗放疗物理与技术

T1/T2直肠癌局部切除或息肉切除后辅助盆腔放疗可替代根治手术

Can adjuvant pelvic radiation therapy after local excision or polypectomy for T1 and T2 rectal cancer offer an alternative option to radical surgery?
PubMed 文献 · Clin Transl Radiat Oncol · 2021-10-14

本研究回顾性分析了15例经局部切除或息肉切除后确诊为T1/T2直肠腺癌且分期为N0M0的成人患者,接受辅助盆腔放疗±同步化疗。中位随访51个月,无局部或区域复发,仅1例在48个月时出现孤立远处转移。提示辅助盆腔放疗可能为偶然发现的早期直肠癌提供替代根治性TME手术的选择。

要点

  • T1/T2直肠癌局部切除或息肉切除后辅助盆腔放疗±同步化疗,中位随访51个月无局部区域复发。
  • 15例患者中80%为T1期,80%接受内黏膜切除,46.6%接受同步化疗。
  • 辅助盆腔放疗可能为偶然发现的早期直肠癌提供替代TME手术的选项。

核心结论

  • 辅助盆腔放疗对局部切除或息肉切除后的T1/T2直肠腺癌显示出良好的局部区域控制。
  • 辅助盆腔放疗可能为偶然发现的早期直肠癌提供替代TME手术的选择。

研究设计与样本

  • 排除复发或已接受全直肠系膜切除(TME)者,最终纳入15例患者。
  • 主要终点为局部区域控制,次要终点包括治疗相关毒性、无病生存、总生存和盆腔复发的手术挽救率。

主要发现

  • 15例患者中位年龄73岁(范围49-82岁),男性9例(60%),女性6例(40%)。
  • 80%为T1期,80%接受内黏膜切除。
  • 中位随访51个月,无局部或区域复发;1例在48个月时出现孤立远处转移,无局部区域复发。

关键数值与推荐

  • 所有患者接受原发灶43-52Gy(EQD2)和盆腔43-48Gy(EQD2)放疗,46.6%接受同步化疗(输注5-FU或口服卡培他滨)。

临床怎么用

  • 对于局部切除或息肉切除后偶然确诊的T1/T2直肠癌N0M0患者,辅助盆腔放疗±同步化疗可作为TME手术的替代方案。

局限性

  • 回顾性研究,样本量小(15例),采用描述性统计分析,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine outcomes after adjuvant pelvic local radiation therapy (RT) +/- concurrent chemotherapy for T1 and T2 rectal carcinomas treated with local excision or polypectomy. METHODS: We retrospectively identified adult patients with histologically proven T1 and T2 rectal adenocarcinoma, diagnosed incidentally at time of local excision or polypectomy between 01 January 2007 and 31 December 2019, and appropriately staged to confirm N0 M0 status. Patients were excluded if they had recurrent cancer or had received total mesorectal excision (TME): anterior resection (AR) or abdominoperineal resection (APR). Patient, tumour and treatment factors, together with disease and toxicity outcomes were collected from institutional medical records, correspondence and investigation reports. Descriptive statistical analyses were employed. The primary endpoint was loco-regional control and secondary endpoints were treatment-related toxicity, disease free survival, overall survival and rate of surgical salvage for pelvic recurrence. RESULTS: The median age of the 15 eligible patients was 73 (range 49-82 years). There were 9 men (60%) and 6 women (40%). The majority had T1 disease (80%) and most had received endomucosal resection (80%). All patients received 43-52Gy (EQD2) to the primary and 43-48Gy (EQD2) to the pelvis with 46.6% receiving concurrent chemotherapy (infusional 5-FU or oral capecitabine). At median follow up of 51 months, there were no local or regional recurrences. One patient experienced an isolated distant relapse at 48 months without any locoregional recurrence. CONCLUSION: Our findings demonstrate good locoregional disease control with the use of adjuvant pelvic RT for T1 and T2 rectal adenocarcinoma initially treated with polypectomy or local (non-oncological) excision. These findings indicate that adjuvant pelvic RT may provide an alternative to TME surgery in patients with incidentally detected early rectal cancers.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Swanton C, Marcus S, Jayamohan J, et al. Can adjuvant pelvic radiation therapy after local excision or polypectomy for T1 and T2 rectal cancer offer an alternative option to radical surgery? Clin Transl Radiat Oncol. 2021. PMID: 34703908. doi:10.1016/j.ctro.2021.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。